Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price was down 11.2% during trading on Thursday . The stock traded as low as $3.57 and last traded at $3.64, with a volume of 606,409 shares changing hands. The stock had previously closed at $4.10.

Several equities analysts have commented on RGLS shares. Chardan Capital lowered their price objective on Regulus Therapeutics from $20.00 to $13.50 and set a “buy” rating for the company in a research report on Tuesday, June 28th. BMO Capital Markets started coverage on Regulus Therapeutics in a research report on Monday, April 11th. They set an “outperform” rating and a $16.00 price objective for the company. Cowen and Company reissued a “buy” rating on shares of Regulus Therapeutics in a research report on Wednesday, June 8th. Wedbush reissued an “outperform” rating and set a $35.00 price objective on shares of Regulus Therapeutics in a research report on Tuesday, June 7th. Finally, Zacks Investment Research raised Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 29th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $10.17.

The stock has a 50-day moving average of $4.15 and a 200-day moving average of $5.84. The company’s market capitalization is $188.16 million.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. On average, equities research analysts expect that Regulus Therapeutics Inc. will post ($1.54) earnings per share for the current year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.